Browse VSNL1

Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00036 EF hand
PF13499 EF-hand domain pair
Function

Regulates (in vitro) the inhibition of rhodopsin phosphorylation in a calcium-dependent manner.

> Gene Ontology
 
Biological Process GO:0001678 cellular glucose homeostasis
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002792 negative regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0006887 exocytosis
GO:0009306 protein secretion
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0017157 regulation of exocytosis
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0032024 positive regulation of insulin secretion
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0035773 insulin secretion involved in cellular response to glucose stimulus
GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0042593 glucose homeostasis
GO:0042886 amide transport
GO:0045921 positive regulation of exocytosis
GO:0046676 negative regulation of insulin secretion
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0060627 regulation of vesicle-mediated transport
GO:0061178 regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:0090278 negative regulation of peptide hormone secretion
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VSNL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VSNL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VSNL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4530.46
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.6780.0885
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4490.594
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4060.492
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0850.932
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8010.517
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0630.931
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4880.651
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2110.846
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.3390.147
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.9730.418
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7860.0179
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of VSNL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VSNL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VSNL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VSNL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VSNL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VSNL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VSNL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVSNL1
Namevisinin-like 1
Aliases VILIP; HPCAL3; HUVISL1; VILIP-1; hippocalcin-like protein 3; VLP-1; Visinin-like protein 1
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VSNL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.